Article Text

Download PDFPDF
Adherence to CF treatment can be improved with the right approach!
  1. André Schultz1,2,3
  1. 1Department of Respiratory Medicine, Perth Children's Hospital, Perth, Western Australia, Australia
  2. 2Wal-yan Respiratory Research Centre, Telethon Kids Institute, University of Western Australia, Perth, Western Australia, Australia
  3. 3Division of Paediatrics, Faculty of Medicine, University of Western Australia, Perth, Western Australia, Australia
  1. Correspondence to Dr André Schultz, Department of Respiratory Medicine, Perth Children's Hospital, Nedlands, Australia; andre.schultz{at}health.wa.gov.au

Statistics from Altmetric.com

The burden of routine, daily therapies prescribed for people with cystic fibrosis (CF) is large. Maintaining adherence to such chronic therapies can be challenging, especially when the financial costs are considerable and they are time consuming, though non-adherence is associated with poor health outcomes.1 Therefore, efforts to improve adherence in people with CF are important, as reflected by the recent global James Lind Alliance Priority Setting Partnership exercise where finding ways to help people with CF to ‘improve and sustain adherence to treatment’ was identified as a priority for the CF community.2

Factors influencing adherence are complex. Non-adherence can be intentional or non-intentional. Patient-related factors include individuals’ understanding of their disease, beliefs about the effectiveness of specific treatments and side effects,3 and the presence or absence of good medication routines.4 External factors that affect adherence include complexity of dosing regimens, cultural factors and the cost of treatments. For people with CF, the reality of living with a chronic disease and having to adhere to complicated treatment regimens inevitably competes with other …

View Full Text

Footnotes

  • Contributors AS wrote the manuscript.

  • Funding AS received salary support from the National Health and Medical Research Council (grant number: APP1193796).

  • Competing interests AS received an honorarium from Vertex Pharmaceuticals for membership on an advisory board.

  • Provenance and peer review Commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Cystic fibrosis
    Martin J Wildman Alicia O’Cathain Chin Maguire Madelynne A Arden Marlene Hutchings Judy Bradley Stephen J Walters Pauline Whelan John Ainsworth Iain Buchan Laura Mandefield Laura Sutton Paul Tappenden Rachel A Elliott Zhe Hui Hoo Sarah J Drabble Daniel Beever CFHealthHub Study Team H Cantrill J Nicholl S Michie S Waterhouse L Robinson A Scott S Antrobus E Lumley AN Biz D Hind C Orchard E Nash J Whitehouse I Ketchall J Rendall H Rodgers C Elston S Bourke W Flight A McGowen N Patel D Watson R Thomas D Shiferaw K Bateman N Bell N Withers C Sheldon M Pasteur D Derry D Waine U Hill J Myers N Shafi C Ohri G Fitch S Madge S Elborn K Miles L Kent V Mills P Moran G King L Funnell J Choyce J Williams C Evans K Dack J Trott A Damani S Raniwalla D Tature A Anderson P Galey L Warnock J Faulkner K Barbour M Thomas H Gledhill K Donohue H Seabridge M Martin K Lee N Robson C Weir L Barlow C Whitton